{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:39:27Z","timestamp":1790221167892,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.vaccine.2015.04.071","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T18:54:44Z","timestamp":1430592884000},"page":"2955-2962","source":"Crossref","is-referenced-by-count":43,"title":["The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-2840","authenticated-orcid":false,"given":"Emma M.","family":"Bentley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart T.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-3815","authenticated-orcid":false,"given":"Nigel J.","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.04.071_bib0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/fmb.13.156","article-title":"Pseudotypes: your flexible friends","volume":"9","author":"King","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0220","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","article-title":"Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison","volume":"89","author":"Wright","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0225","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0230","first-page":"309","article-title":"The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes","volume":"7","author":"Ferrara","year":"2012","journal-title":"J Mol Genet Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0235","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2217\/fvl.13.60","article-title":"Current progress with serological assays for exotic emerging\/re-emerging viruses","volume":"8","author":"Mather","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0240","doi-asserted-by":"crossref","first-page":"7178","DOI":"10.1016\/j.vaccine.2009.09.024","article-title":"A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa","volume":"27","author":"Wright","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0245","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2010.09.014","article-title":"Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses","volume":"408","author":"Wright","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0250","first-page":"4","article-title":"Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies","volume":"201","author":"Molesti","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/gt.2011.124","article-title":"Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies\/vesicular stomatitis virus chimeric envelope glycoprotein","volume":"19","author":"Carpentier","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0260","first-page":"1","article-title":"Current status of rabies and prospects for elimination","volume":"6736","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00161","article-title":"Pseudotype-based neutralization assays for influenza: a systematic analysis","volume":"6","author":"Carnell","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0270","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2009.07.079","article-title":"Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses","volume":"27","author":"Alberini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0275","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/vaccines2040707","article-title":"Overview of serological techniques for influenza vaccine evaluation: past, present and future","volume":"2","author":"Trombetta","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0285","first-page":"286158","article-title":"Comparative serological assays for the study of h5 and h7 avian influenza viruses","volume":"2013","author":"Molesti","year":"2013","journal-title":"Influenza Res Treat"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0290","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.vaccine.2007.02.039","article-title":"Comparison of neutralising antibody assays for detection of antibody to influenza A\/H3N2 viruses: an international collaborative study","volume":"25","author":"Stephenson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jviromet.2014.09.021","article-title":"Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay-based diagnostic kit","volume":"210","author":"Mather","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0300","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1128\/JVI.01379-08","article-title":"Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120","volume":"82","author":"Forsman","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0305","doi-asserted-by":"crossref","first-page":"e17665","DOI":"10.1371\/journal.pone.0017665","article-title":"Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules","volume":"6","author":"Hultberg","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0310","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0315","first-page":"304","article-title":"The use of equine influenza pseudotypes for serological screening","volume":"6","author":"Scott","year":"2012","journal-title":"J Mol Genet Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0320","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/mt.2012.61","article-title":"A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors","volume":"20","author":"Ho","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0325","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0335","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0340","doi-asserted-by":"crossref","first-page":"e62778","DOI":"10.1371\/journal.pone.0062778","article-title":"Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine","volume":"8","author":"Powell","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0345","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0350","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/srep06154","article-title":"Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route","volume":"4","author":"Carey","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0355","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2011.12.026","article-title":"Coated microneedle arrays for transcutaneous delivery of live virus vaccines","volume":"159","author":"Vrdoljak","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0360","doi-asserted-by":"crossref","first-page":"e22442","DOI":"10.1371\/journal.pone.0022442","article-title":"Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice","volume":"6","author":"Carey","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0365","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.1214449110","article-title":"Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays","volume":"110","author":"Bachy","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0370","doi-asserted-by":"crossref","first-page":"19940","DOI":"10.1073\/pnas.0907898106","article-title":"Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1","volume":"106","author":"Benlahrech","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0375","doi-asserted-by":"crossref","first-page":"e48038","DOI":"10.1371\/journal.pone.0048038","article-title":"Fragmentation of SIV-gag vaccine induces broader T cell responses","volume":"7","author":"Benlahrech","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0380","doi-asserted-by":"crossref","first-page":"e88327","DOI":"10.1371\/journal.pone.0088327","article-title":"Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses","volume":"9","author":"Herath","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0385","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nm.1967","article-title":"Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys","volume":"15","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0390","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0395","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0400","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jgm.1602","article-title":"Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog","volume":"13","author":"Koo","year":"2011","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0405","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nbt815","article-title":"Continuous high-titer HIV-1 vector production","volume":"21","author":"Ikeda","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/379085a0","article-title":"Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase","volume":"379","author":"Takeuchi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0415","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.4049\/jimmunol.1301195","article-title":"Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts","volume":"191","author":"Scobie","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.04.071_bib0420","doi-asserted-by":"crossref","first-page":"e1002442","DOI":"10.1371\/journal.ppat.1002442","article-title":"Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41","volume":"7","author":"Lai","year":"2011","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15005472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15005472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T19:50:40Z","timestamp":1537645840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15005472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":42,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0264410X15005472"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}